Brazil has become one of the most closely watched destinations in global medical cannabis trade. Since ANVISA (Agencia Nacional de Vigilancia Sanitaria) authorised the importation of cannabis-based products in 2015 and expanded its framework through subsequent resolutions, the country's medical channel has grown steadily, drawing interest from Canadian Licensed Producers looking for new B2B export markets.
For a Canadian LP, exporting to Brazil means navigating two regulatory systems at once: the export authorisation process under the Cannabis Act and Cannabis Regulations on the Canadian side, and ANVISA's import permit and product registration requirements on the Brazilian side. This guide covers both, with practical notes on documentation, supply chain structure, and what Brazilian importers typically expect from a Canadian supply partner.
Brazil does not permit the import of dried cannabis flower in the same commodity format that Germany or Australia use. The ANVISA framework centres on cannabis-derived products (oils, extracts, finished pharmaceutical forms) and cannabis starting material supplied to licensed Brazilian manufacturers. Understanding this structure upfront is essential before approaching any Brazilian counterpart.
Note: Brazil's cannabis regulatory framework is evolving. ANVISA updates its resolutions periodically, and import requirements can change. Verify current ANVISA authorisation requirements with a qualified Brazilian regulatory counsel before initiating a shipment.
Brazil's medical cannabis import framework under ANVISA
Brazil's cannabis regulatory framework is administered by ANVISA, the country's federal health surveillance agency. Established in 1999 to oversee health products and services, ANVISA issued its first cannabis-specific resolution in 2015 and has progressively expanded the framework since. The current anchor is Resolution RDC 660/2022, which governs the registration, importation, and commercialisation of cannabis-based products in the medical channel. By 2023, ANVISA had authorised over 100 cannabis products for commercialisation in Brazil, with the majority sourced from international suppliers. Domestic production capacity, while growing, still meets only a fraction of demand.
Here is the structural point every Canadian LP must understand before entering this market: ANVISA authorises cannabis imports for medical and scientific purposes, but the regulatory model is built around finished or semi-finished pharmaceutical products and starting material for licensed processors. It is not raw dried flower sold as a commodity. Your entry point is a supply agreement with a Brazilian company that holds an ANVISA manufacturing or importation licence.
ANVISA-licensed Brazilian entities fall into two categories relevant to Canadian LP supply. The first is licensed manufacturers, who import cannabis starting material for processing into finished medical products. The second is licensed importers of finished cannabis-based medicines. In 2026, Brazil's domestic production capacity remains limited, and a meaningful share of the country's medical cannabis supply still enters via import channels, which keeps Canadian product competitive.
At the international level, both the International Narcotics Control Board (INCB) framework and the Single Convention on Narcotic Drugs govern cross-border cannabis movement. Brazil and Canada are both signatories. Health Canada will not issue an export permit for a shipment to Brazil without confirmation that the corresponding ANVISA import authorisation exists. The two permits must align before any goods move.
The Canadian LP's export permit process under the Cannabis Act
Exporting cannabis to Brazil starts with Health Canada's export permit process under the Cannabis Act and Section 62 of the Cannabis Regulations. A standard cultivation or processing licence does not automatically authorise export. You'll need export authorisation as part of your licence conditions, and a separate permit for each individual shipment.
For a full walkthrough of each step, AlphaLeaf's guide to the cannabis export permit application covers the process in detail. In brief, the Health Canada application requires:
- Your licence number and legal entity details
- The Brazilian importer's name, address, and ANVISA authorisation number
- Product description (form, cannabinoid content, quantity in grams)
- Proposed port of exit and shipping method
- The period during which the shipment will occur
- Confirmation that the destination country has issued or will issue an import authorisation
Health Canada typically processes export permit applications within 15 to 30 business days, though timelines shift based on application completeness and queue volume. An incomplete application submitted before the Brazilian partner has secured its ANVISA authorisation will push that timeline out significantly. Run both sides of the permit process in parallel from the start.
One meaningful difference from the Germany export pathway: Brazil has no formal Mutual Recognition Agreement with Canada covering cannabis GMP. In the German channel, EU-GMP alignment is well established and the BAFA export authorisation process runs within a reasonably understood bilateral framework. For Brazil, your quality documentation has to stand on its own before ANVISA. That raises the documentation bar, and it's why EU-GMP-aligned practices give you an advantage here even when they aren't formally required. See AlphaLeaf's comparison of EU-GMP versus Health Canada GMP for context on what that alignment involves in practice.
Documentation and quality standards: what Brazilian importers expect
When you approach an ANVISA-licensed Brazilian partner, your compliance documentation is evaluated as carefully as your product specs. ANVISA holds importers accountable for the quality of goods that enter Brazil, so a Brazilian company choosing a Canadian supplier is directly putting its own licence on the line. Documentation gaps are deal-breakers, not negotiating points.
Certificate of Analysis
Every shipment needs a COA from an ISO/IEC 17025-accredited laboratory. The COA must cover cannabinoid potency (THC, CBD, CBG, CBN at minimum), terpene profile, residual solvent screening, heavy metals, pesticide residues, microbial contamination, and moisture content. ANVISA-licensed importers typically want the test methods referenced against Brazilian pharmacopoeial standards or internationally recognised equivalents. For a detailed breakdown of how to read and present a cannabis COA to an international buyer, see AlphaLeaf's COA guide for B2B buyers.
GMP documentation
ANVISA expects evidence of GMP-compliant production. There's no bilateral recognition agreement, but Canadian LPs with EU-GMP-aligned or PIC/S GMP-compliant quality systems have a real structural advantage. Health Canada is a PIC/S member, and its GMP inspection reports carry weight in ANVISA review even without a formal MRA. LPs that haven't yet pursued EU-GMP alignment should read AlphaLeaf's EU-GMP certification guide to understand what the upgrade path looks like.
Batch traceability records
Full chain-of-custody documentation from cultivation through processing, testing, and packaging is non-negotiable. Your Brazilian partner needs to show ANVISA that the product they received matches what they ordered, with no gaps. Batch records, processing records, and seed-to-sale logs should be available in English, with certified Portuguese translations ready on request.
The Canada-Brazil LP export documentation checklist
Before any goods leave your facility, have these ready:
- Health Canada export permit (original or certified copy)
- ANVISA import authorisation from your Brazilian partner (copy)
- ISO 17025-accredited Certificate of Analysis for the specific batch
- Certificate of Origin (LP letterhead or Canadian Chamber of Commerce)
- Commercial invoice and packing list
- Bill of lading or airway bill
- GMP compliance documentation or PIC/S inspection summary
- Phytosanitary certificate (if required by Brazilian customs for the product form)
Packaging and labelling must also meet ANVISA's requirements for imported cannabis products. Labels need your Health Canada licence number, the ANVISA authorisation number of the importer, cannabinoid content, lot number, and expiry or best-before date. AlphaLeaf's guide to cannabis export packaging and labelling covers what Canadian LPs need to account for when preparing product for international shipment.
Supply chain structure and practical timelines for 2026
Canada-to-Brazil cannabis trade in 2026 runs almost entirely through air freight. Brazil's customs processing times for sea freight make it impractical for perishable goods, and most shipments arrive via São Paulo's Guarulhos International Airport (GRU), where ANVISA maintains a customs oversight presence. Product can't be released to your Brazilian partner until ANVISA clearance is complete at point of entry.
Dried cannabis and extracts don't require refrigeration, but humidity-controlled packaging is essential to maintain quality across the transit period. Your packaging also needs to meet ANVISA's labelling standards: Health Canada licence number, ANVISA authorisation number of the importer, cannabinoid content, lot number, and expiry or best-before date on every unit.
Plan your timelines carefully. A Health Canada export permit takes 15 to 30 business days to process. Add ANVISA import authorisation lead time on the Brazilian side (variable by importer and product category), plus customs clearance at GRU, plus the initial due diligence phase between you and your new partner. A realistic first-shipment timeline is four to six months from signed agreement to product delivery. Set that expectation with your Brazilian counterpart at the beginning of the relationship, not after the delays start.
Brazilian importers typically transact in USD for international supply. Exchange rate volatility between the Brazilian real and USD has been a recurring commercial variable for importers, and it affects order volumes and payment timing in ways that aren't always predictable. Letters of credit are standard for first shipments. Repeat trade tends to move to open-account terms once a supply relationship is established. Build currency and payment structure into your contract terms from the outset.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower. We hold export authorisation under the Cannabis Act and maintain PIC/S-compatible quality systems, ISO 17025-certified batch testing, and full batch traceability records that ANVISA-licensed Brazilian importers need from a Canadian supply partner. Our compliance documentation is structured to support both the Health Canada permitting process and partner-side submissions to ANVISA. Contact us at alphaleaf.ca to discuss your supply requirements.
Frequently Asked Questions
Can Canadian LPs export dried cannabis flower directly to Brazil?
Not to end consumers or dispensaries. Brazil's ANVISA framework focuses on cannabis-derived products and cannabis starting material for licensed manufacturers. Canadian LPs typically supply ANVISA-authorised Brazilian importers or licensed manufacturers who process imported material into finished medical products.
What export permit does a Canadian LP need to ship cannabis to Brazil?
A Canadian LP must obtain an export permit from Health Canada under the Cannabis Regulations (Section 62) for each shipment. The application requires the Brazilian importer's ANVISA authorisation, the shipment quantity and form, and confirmation that the destination country's import authorisation is in effect.
What does ANVISA require for a Brazilian company to import cannabis from Canada?
The Brazilian importer must hold a valid ANVISA import authorisation under Resolution RDC 660/2022. The importing company must be a licensed pharmaceutical manufacturer or distributor, and the product must meet ANVISA quality and labelling specifications for imported cannabis.
Does Brazil recognise Health Canada GMP certification?
There is no formal mutual recognition agreement between Health Canada and ANVISA for cannabis GMP. However, ANVISA accepts documentation aligned with PIC/S GMP standards. Since Health Canada is a PIC/S member, its GMP inspection reports carry weight in ANVISA review. Canadian LPs with EU-GMP-aligned or PIC/S-compliant quality systems are well positioned for ANVISA partner review.
What documentation should a Canadian LP prepare for a Brazil export shipment?
Required documentation includes: the Health Canada export permit, an ISO 17025-accredited Certificate of Analysis, Certificate of Origin, bill of lading, commercial invoice, packing list, the Brazilian importer's ANVISA authorisation number, and phytosanitary certificates if required. Full batch traceability records are expected by ANVISA-licensed importers and should be available in English with certified Portuguese translations on request.
